Compare KREF & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KREF | DCTH |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.8M | 363.5M |
| IPO Year | N/A | 2015 |
| Metric | KREF | DCTH |
|---|---|---|
| Price | $6.51 | $11.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $7.88 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 1.3M | 252.6K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.49% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | N/A |
| Revenue This Year | $545.92 | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | ★ N/A | $157.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $8.12 |
| 52 Week High | $9.98 | $18.23 |
| Indicator | KREF | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 66.38 |
| Support Level | $5.87 | $10.50 |
| Resistance Level | $6.90 | $11.99 |
| Average True Range (ATR) | 0.24 | 0.41 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 74.85 | 96.68 |
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.